📰 Research Models News
Page 9 - Research Models News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Research Models. Real-time updates on events, politics, business and more.
February 15, 2024
Charles River Laboratories International (NYSE:CRL – Get Free Report) had its price target lifted by Evercore ISI from $260.00 to $265.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s target price would indicate a potential upside of 8.54% from […]
February 15, 2024
Charles River Laboratories International (NYSE:CRL – Get Free Report) announced its earnings results on Wednesday. The medical research company reported $2.46 earnings per share for the quarter, topping the consensus estimate of $2.39 by $0.07, Briefing.com reports. Charles River Laboratories International had a net margin of 11.27% and a return on equity of 18.15%. The […]
February 15, 2024
Charles River Laboratories International (NYSE:CRL – Get Free Report) released its earnings results on Wednesday. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.07, Briefing.com reports. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. […]
February 14, 2024
Charles River Laboratories International (NYSE:CRL – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 10.900-11.400 for the period, compared to the consensus earnings per share estimate of 10.790. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the […]
February 13, 2024
State of New Jersey Common Pension Fund D decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 2.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 28,786 shares of the medical research company’s stock after selling 806 shares during the […]
February 13, 2024
Anchor Capital Advisors LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 4.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 119,274 shares of the medical research company’s stock after selling 5,308 shares […]
February 8, 2024
By Chris Wack Inotiv shares were up 22% to $4.50 after the company reported a first-quarter loss that was less than analysts' expectations. The contract...
February 4, 2024
Bryn Mawr Capital Management LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,809 shares of the medical research company’s stock after […]
February 3, 2024
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 […]
January 30, 2024
Zions Bancorporation N.A. raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 28.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,727 shares of the medical research company’s stock after buying an additional 1,473 shares during the quarter. […]